Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects

ConclusionsCo-administration of IMEG with MET or SITA did not result in clinically relevant changes in systemic exposure to MET or SITA, although minor reductions in exposure (AUC0 –τ and maximum concentration) and renal elimination were noted when MET was given with IMEG vs placebo.Clinical Trial RegistrationEudraCT2009-014520-40 (MET-IMEG DDI) and EudraCT2010-022926-34 (SITA-IMEG DDI)
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research